Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays

SMITALOVÁ, Dagmar, D. DVORAKOVA, Zdeněk RÁČIL and Marianna ROMŽOVÁ. Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays. Practical Laboratory Medicine. AMSTERDAM: ELSEVIER, 2021, vol. 25, MAY, p. nestrankovano, 6 pp. ISSN 2352-5517. Available from: https://dx.doi.org/10.1016/j.plabm.2021.e00210.

Basic information

• Original name: Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays
• Authors: SMITALOVÁ, Dagmar (203 Czech Republic, belonging to the institution), D. DVORAKOVA, Zdeněk RÁČIL (203 Czech Republic) and Marianna ROMŽOVÁ (703 Slovakia, belonging to the institution).
• Edition: Practical Laboratory Medicine, AMSTERDAM, ELSEVIER, 2021, 2352-5517.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14740/21:00120108
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.1016/j.plabm.2021.e00210
• UT WoS: 000653682600011
• Keywords in English: Chronic myeloid leukemia; BCR-ABL1 monitoring; GeneXpert BCR-ABL Monitor assay; RT-qPCR; Digital PCR
• Tags: 14110212, podil, rivok
• Tags: International impact, Reviewed

Abstract

BCR-ABL1 molecular detection using quantitative PCR (qPCR) methods is the golden standard of chronic myeloid leukemia (CML) monitoring. However, due to variable sensitivity of qPCR assays across laboratories, alternative methods are tested. Digital PCR (dPCR) has been suggested as a robust and reproducible option. Here we present a comparison of droplet dPCR with routinely used reverse-transcription qPCR (RT-qPCR) and automated GeneXpert systems. Detection limit of dPCR was above 3 BCR-ABL1 copies, although due to background amplification the resulting sensitivity was 0.01% BCR-ABL1 (MR4.0). Nevertheless, in comparison with GeneXpert, dPCR categorized more than 50% of the patients into different MR groups, showing a potential for improved BCR-ABL1 detection.

Links

• MUNI/A/1105/2018, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Acronym: VýDiTeHeMA VI)

Investor: Masaryk University, Category A

• MUNI/A/1395/2019, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII (Acronym: VýDiTeHeMa VII)

Investor: Masaryk University, Category A

• NV17-30397A, research and development project: Name: Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1